Product Information
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use BAQSIMI safely and effectively. See full prescribing information for BAQSIMI.
BAQSIMI (glucagon) nasal powder
Initial U.S. Approval: 1960
INDICATIONS AND USAGE
BAQSIMI™ is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above. (1)
DOSAGE AND ADMINISTRATION
- BAQSIMI is for intranasal use only. (2.1)
- The recommended dose of BAQSIMI is 3 mg administered as one actuation of the intranasal device into one nostril. (2.2)
- Administer BAQSIMI according to the printed instructions on the shrink-wrapped tube label and the Instructions for Use. (2.1)
- Administer the dose by inserting the tip into one nostril and pressing the device plunger all the way in until the green line is no longer showing. The dose does not need to be inhaled. (2.1)
- Call for emergency assistance immediately after administering the dose. (2.1)
- When the patient responds to treatment, give oral carbohydrates. (2.1)
- Do not attempt to reuse BAQSIMI. Each BAQSIMI device contains one dose of glucagon and cannot be reused. (2.1)
- If there has been no response after 15 minutes, an additional 3 mg dose may be administered while waiting for emergency assistance. (2.2)
DOSAGE FORMS AND STRENGTHS
Nasal powder: intranasal device containing one dose of glucagon 3 mg (3)
CONTRAINDICATIONS
- Pheochromocytoma (4)
- Insulinoma (4)
- Known hypersensitivity to glucagon or to any of the excipients (4)
WARNINGS AND PRECAUTIONS
- Substantial Increase in Blood Pressure in Patients with Pheochromocytoma: Contraindicated in patients with pheochromocytoma because BAQSIMI may stimulate the release of catecholamines from the tumor. (4, 5.1)
- Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, BAQSIMI may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously. (4, 5.2)
- Hypersensitivity and Allergic Reactions: Allergic reactions have been reported and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension. (4, 5.3)
- Lack of Efficacy in Patients with Decreased Hepatic Glycogen: BAQSIMI is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for BAQSIMI to be effective. Patients with these conditions should be treated with glucose. (5.4)
ADVERSE REACTIONS
Most common (≥10%) adverse reactions associated with BAQSIMI are nausea, vomiting, headache, upper respiratory tract irritation (i.e., rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis), watery eyes, redness of eyes, itchy nose, throat and eyes. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
- Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. (7.1)
- Indomethacin: In patients taking indomethacin BAQSIMI may lose its ability to raise glucose or may produce hypoglycemia. (7.2)
- Warfarin: BAQSIMI may increase the anticoagulant effect of warfarin. (7.3)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 10/2020
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
PATIENT PACKAGE INSERT
INSTRUCTIONS FOR USE
Revised: 10/2020
Document Id: 3928d4ab-2923-4932-91cb-d18870b0972e
Set id: 3fdb4e92-2e19-487d-9f14-99871e9fd15a
Version: 5
Effective Time: 20201027